Correction: Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients.

[This corrects the article DOI: 10.1371/journal.pone.0203878.].

There are errors in Table 1. There are multiple incorrect abbreviations in the first column. Please see the corrected Table 1 here.

Table 1

Baseline characteristics of CKD stage 3–4, CKD stage 5-ESRD, and non-CKD groups.

Characteristics	Non-CKD group (A)	CKD stage3–4 group (B)	CKD stage5-ESRD (C)	P value	Post-hoc†
Total	8213 (90.2%)	730 (8.0%)	166 (1.8%)
Mean age (years)	58.08±14.15	72.30±12.10	62.45±13.20	0.0001	A<C<B
Gender (Male %)	4115 (50.1%)	331 (45.3%)	80 (48.1%)	0.044	A>B>C
Presence of chronic illness (% by groups)
HTN	1864 (22.7%)	413 (56.6%)	95 (57.2%)	<0.0001	A<B<C
DM	1462 (17.8%)	300 (41.1%)	83 (50.0%)	<0.0001	A<B<C
CVD	987 (12.0%)	216 (29.6%)	51 (30.7%)	<0.0001	A<B<C
LC	179 (2.2%)	28 (3.8%)	9 (5.4%)	0.001	A<B<C
CHF	109 (1.3%)	70 (9.6%)	17(10.2%)	0.0001	A<B<C
COPD	78 (0.9%)	17 (2.3%)	2 (1.2%)	0.002	A<C<B
eGFR (ml/min/1.73 m2)	92.78±14.86	44.49±12.06	7.33±3.19	<0.0001	C<B<A

CKD, chronic kidney disease; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; HTN, hypertension; DM, diabetes mellitus; CVD, cardiovascular disease; LC, liver cirrhosis; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease. eGFR was calculated using CKD-EPI formula. Age and eGFR are presented as mean ± standard deviation (SD). Nominal data are presented as percentages

†p-value by student t-test or chi-squared/fisher exact test and adjusted by bonferroni correction